Benzinga | Aug 12, 2020 05:29AM EDT

Morgan Stanley Downgrades Fulcrum Therapeutics to Equal-Weight, Lowers Price Target to $11

Morgan Stanley analyst Matthew Harrison downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Overweight to Equal-Weight and lowers the price target from $29 to $11.